Abstracts tagged "B cells"

Abstract Number: 986 • 2014 ACR/ARHP Annual Meeting
Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjogren’s Syndrome Pathogenesis
Yoshiaki Kassai¹, Katsuya Suzuki², Rimpei Morita³, Maiko Takiguchi¹, Rina Kurisu¹, Takahiro Miyazaki¹, Akihiko Yoshimura³ and Tsutomu Takeuchi², ¹Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Whole blood flow cytometric analysis and serum protein profiling were commonly utilized to characterize disease-specific alterations in a wide variety of autoimmune diseases. However,…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
Abstract Number: 2870 • 2014 ACR/ARHP Annual Meeting
B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus
Shaun W. Jackson^1,2, Nicole Scharping¹, Socheath Khim¹ and David Rawlings^1,2, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics, University of Washington, Seattle, WA
Background/Purpose Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and patients with SLE frequently express a “type 1 IFN gene signature”. Type 1…
Abstract Number: 1947 • 2014 ACR/ARHP Annual Meeting
Prolactin Promotes Survival of Immature B Cells from MRL/Lpr Mice
Karina Chavez-Rueda¹, Rocio Flores-Fernández¹, Francisco Blanco-Favela¹, María Legorreta-Haquet², Luis Chávez-Sánchez², Rafael Hernández-González³ and Emiliano Tesoro-Cruz³, ¹UIM en Inmunologia, IMSS, Mexico DF, Mexico, ²IMSS, Mexico DF, Mexico, ³Departamento de Investigación Experimental y Bioterio, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico DF, Mexico
Background/Purpose Prolactin (PRL) plays an important role in modulating the immune response. PRL is secreted by the pituitary gland as well as many other organs…
Abstract Number: 1000 • 2014 ACR/ARHP Annual Meeting
Pathogenic Role of CXC Chemokine receptor 3-Positive B Cells in Bone Destruction of Rheumatoid Arthritis
Yuri Hirosaki, Hiroaki Niiro, Shun-ichiro Ota, Naoko Ueki, Hirofumi Tsuzuki, Kumiko Noda, Siamak Jabbarzadeh-Tabrizi, Hiroki Mitoma, Yojiro Arinobu, Mitsuteru Akahoshi, Hiroshi Tsukamoto and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose ：B cells can function as potent effector cells by production of autoantibody, immune complex formation and inflammatory cytokines. Clinical efficacy of B-cell depletion therapy…
Abstract Number: 2872 • 2014 ACR/ARHP Annual Meeting
B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snRNP Reactive B Cells in BXD2 Mice
Jennie Hamilton¹, Jun Li², Qi Wu³, PingAr Yang³, Bao Luo³, Hao Li⁴, Troy Randall⁵, John Edwin Bradley⁵, Justin J. Taylor⁶, John D. Mountz^7,8 and Hui-Chen Hsu^3,4, ¹University of Alabama at Birmingham, Birmingham, AL, ²Med - Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL, ⁸Birmingham VA Medical Center, Birmingham, AL
Background/Purpose Systemic lupus erythematous (SLE) is characterized by production of highly pathogenic IgG autoantibodies (autoAbs). While serum autoAb profiling is standard, it remains challenging to…
Abstract Number: 1946 • 2014 ACR/ARHP Annual Meeting
CD22 Is Required for Formation of Memory B Cell Precursors within Germinal Centers
Craig Chappell, Kevin Draves and Edward Clark, Immunology, University of Washington, Seattle, WA
Background/Purpose CD22 is a sialic-acid binding co-receptor expressed primarily on B cells that has a number of functions including adhesion, regulation of B cell homeostasis and…
Abstract Number: 999 • 2014 ACR/ARHP Annual Meeting
Microrna-155 As an Epigenetic Regulator of B-Cell Activation in Rheumatoid Arthritis: In Vivo and in Vitro Evidences
Stefano Alivernini¹, Barbara Tolusso¹, Silvia Canestri¹, Luca Petricca¹, Clara Di Mario², Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Pathology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: MicroRNAs (miRs) are a novel class of post-transcriptional regulators. miR-155 was shown to be a regulator of B cell biology in haematological diseases as…
Abstract Number: 2873 • 2014 ACR/ARHP Annual Meeting
Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling
Alison Maloney¹, Drew Hotson², Stephen Rapecki¹, Gianluca Fossati¹, Simon Lumb¹, David Rosen², Santosh Putta², Nikil Wale², David Spellmeyer², Alessandra Cesano², Rachael Hawtin² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Nodality Inc., South San Francisco, CA
Background/Purpose Epratuzumab is a humanized monoclonal antibody targeting the B cell-specific protein CD22 and is in Phase 3 clinical trials in patients with systemic lupus…
Abstract Number: 1945 • 2014 ACR/ARHP Annual Meeting
Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Patients with Systemic Lupus Erythematosus
Anthony Shock¹, Brian Kilgallen², Willem Koetse², Christian Stach³, Sabine Bongardt³ and Catrinel Galateanu⁴, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Raleigh, NC, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose Epratuzumab is a humanized monoclonal antibody (mAb) that targets the B cell-specific protein CD22 and is currently in Phase 3 clinical trials in patients…
Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting
β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10
Georg Pongratz¹, Clemens Wiest², Madlen Melzer² and Rainer Straub³, ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…
Abstract Number: 2836 • 2014 ACR/ARHP Annual Meeting
Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
Michelle Petri¹, Renee S. Martin², Colin Hislop², Morton A. Scheinberg³ and Richard Furie⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Anthera Pharmaceuticals Inc, Hayward, CA, ³Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁴Division of Rheumatology and Allergy-Clinical Immunology, North Shore - Long Island Jewish Health System, Great Neck, NY
Background/Purpose: To conduct secondary endpoint analyses of the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on patient-reported outcomes and…
Abstract Number: 1944 • 2014 ACR/ARHP Annual Meeting
Targeting CD22 with Epratuzumab Impacts Cytokine Production By B Cells
Vanessa Fleischer^1,2, Julia Sieber^1,2, Sarah J. Fleischer^3,4, Anthony Shock⁵, Guido Heine⁶, Capucine Daridon^1,2 and Thomas Dörner^1,2, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²German Rheumatism Research Centre Berlin, Berlin, Germany, ³Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Dermatology, Venerology and Allergology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose CD22 is a negative co-receptor of the B-cell receptor (BCR) and, when targeted by epratuzumab, partially inhibits BCR signaling, for example by reducing Syk…
Abstract Number: 995 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Have Alterations in Inherently Autoreactive 9G4+ B-Cell Subpopulations in Peripheral Blood
Rita A. Moura^1,2, Maria J. Leandro³, Venkat Reddy¹, João E. Fonseca^2,4 and Geraldine Cambridge³, ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose B-cells utilizing the VH-region immunoglobulin gene VH4-34 produce natural autoreactive antibodies. The rat monoclonal antibody 9G4 recognizes B-cells with VH4-34-encoded B-cell receptors (9G4+ B-cells)…
Abstract Number: 2820 • 2014 ACR/ARHP Annual Meeting
Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation
Nida Meednu¹, Hengwei Zhang², Teresa Owen³, Lianping Xing⁴ and Jennifer H. Anolik⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose Rheumatoid arthritis (RA) is a systemic autoimmune disease that often leads to joint damage, a process mediated by an imbalance between bone resorption and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.